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Introduction {#sec0005}
============

Chikungunya is an arboviral disease caused by chikungunya viral (CHIKV) infection that is transmitted to humans by infected mosquitoes of the *Aedes* genus ([@bib0205], [@bib0220]). CHIKV was first identified in Tanzania in 1953 ([@bib0170]). Since then it was transmitted to South and Southeast Asia, Africa, and Europe ([@bib0205], [@bib0255], [@bib0080]). In the Western Hemisphere, however, the first locally-transmitted infection occurred in December 2013 ([@bib0155], [@bib0140], [@bib0250]) in the Caribbean ([@bib0115], [@bib0265]). By the end of 2014, \>1.1 million suspect cases were reported in the Americas ([@bib0190]). In 2016 alone, there were over 500,000 cumulative CHIKV cases ([@bib0190]). In Canada, 479 confirmed and probable cases were diagnosed in 2014 ([@bib0095]), of which, 128 cases were imported ([@bib0190]).

The disease is characterized by acute-onset of high grade fever, severe arthralgia, followed by maculopapular rash ([@bib0270]). CHIKV is usually self-limited, with the majority of symptoms typically resolving in 7-10 days ([@bib0205]). Generally, overall mortality is low but there exists a risk for severe disease and death associated with CHIKV infection ([@bib0215]). Rheumatologic symptoms and neurologic, carditis, respiratory, renal, and ocular manifestations are among the severe sequelae of CHIKV ([@bib0220], [@bib0170], [@bib0230], [@bib0045], [@bib0210]). When developed, these conditions can persist for several months or years after acute infection ([@bib0230], [@bib0045], [@bib0235], [@bib0040], [@bib0150]). Furthermore, CHIKV is a common cause of virus-induced arthritis in the Eastern Hemisphere, with documented epidemics in Africa, Southeast Asia, and the Indian Ocean islands ([@bib0240], [@bib0015], [@bib0100], [@bib0160]).

Epidemiologic evidence suggests that CHIKV patients at risk of severe disease outcomes are elderly subjects ([@bib0110]) and those with certain comorbidities, *e.g.*, obesity ([@bib0180]), diabetes ([@bib0130]), cardiac diseases ([@bib0010]), and asthma ([@bib0185]). The presence of these comorbidities was proposed to predispose CHIKV patients to severe complications of the viral infection ([@bib0180], [@bib0130], [@bib0010], [@bib0185]). However, the prevalence of co-existing medical conditions in severe CHIKV cases has not been described. A systematic evaluation and detailed estimate for the prevalence of comorbidities in CHIKV severe cases may aid the public health sector in developing policies for surveillance, preparedness and response to the infection and its severe outcomes. The present study was undertaken to evaluate the prevalence of co-existing chronic conditions in CHIKV patients and in severe cases. We conducted a systematic review and meta-analysis of published literature to describe the frequency of chronic comorbidities in CHIKV and to explore their possible contributions to the severity and complication of this viral condition.

Methods {#sec0010}
=======

Search strategy and selection criteria {#sec0015}
--------------------------------------

A search was conducted in PubMed, Ovid MEDLINE, Embase and Embase Classic databases to the last week of July 2017 using the search terms (MeSH) "Chikungunya" AND "Diabetes, Hypertension, Stroke, Cardiovascular Diseases, Coronary Artery Diseases, Obesity, OR Asthma". Limiting the search to English language resulted in 111 articles. When these articles were restricted to studies in human and deduplicated, 82 abstracts were searched for title and abstract review as they satisfied our selection criteria (see below). We excluded reports published as review articles, letters, editorials, conference abstracts, case reports (with less than 3 cases) or vaccination trials. Only 20 articles were considered for full text review (see [Figure 1](#fig0005){ref-type="fig"} ). Ten articles were excluded at the full text review stage as they were either not related to the study objectives (4 studies), not reporting prevalence of chronic disease in CHIKV (3 studies), case reports with small numbers of cases (i.e., \<3 cases; 2 reports), or a review article (see [Figure 1](#fig0005){ref-type="fig"} and Supplementary Table S1). After identifying one study through bibliography searching, 11 reports were included for systematic review and meta-analysis ([@bib0015], [@bib0100], [@bib0180], [@bib0130], [@bib0225], [@bib0200], [@bib0075], [@bib0050], [@bib0070], [@bib0245], [@bib0035]).Figure 1Systematic literature review process.The PRISMA flowchart describes the systematic review of literature for the proportion of comorbidities in chikungunya. A total of 11 unique studies were identified from an initial 98 examined titles.Figure 1

Inter-reviewer agreement {#sec0020}
------------------------

The abstracts of the identified studies were independently reviewed by two readers (SGR and SY). Differences were resolved through discussions for a consensus to be reached. Percentage agreement and Cohen's Kappa (κ) statistic ([@bib0065]) were calculated and interpreted in accordance with Landis and Koch's benchmarks ([@bib0145]) for assessing the agreement between reviewers as poor (\<0), slight (0.0-0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80), and excellent (0.81-1.0). The agreement on the inclusion between the two reviewers was 93%, with κ = 0.68 (95% CI: 0.38-0.97).

Data extraction and analysis {#sec0025}
----------------------------

Data extracted from the selected studies included the first author's name, publication date, country, dates of recruitment, total sample size (divided to males and females), age estimates (from reported mean, median or the mid-point for age range of the highest subject frequency), prevalence of symptoms (including pyrexia, arthralgia, cephalgia, myalgia, joint edema, dermatitis, and malaise) and percentage of comorbidities including diabetes (both type I and type II, if separately mentioned), hypertension, heart diseases (combined from cardiovascular disease, coronary artery disease, coronary vascular disease, atrial fibrillation, chronic ischemic heart disease, acute coronary syndrome for duration less than 6 months, cardiac disorder, cardiac heart failure, and congestive cardiac failure), asthma (not including chronic obstructive pulmonary disease), stroke, and obesity. The prevalence of comorbidities was measured by extracting the proportion of co-existing medical conditions from CHIKV cases and from severe disease outcome. Severe CHIKV was identified as cases that underwent ICU, those with acute diseases (*e.g.,* acute encephalitis) and subjects with atypical CHIKV (atypical clinical manifestations of CHIKV include vesiculobullous lesions, febrile seizures, and meningoencephalitis), joints involvement (e*.g.,* inflammatory joint destruction), hospitalization, and/or death. The primary outcome measure was to evaluate the overall prevalence of comorbidities in the CHIKV infection and stratify the estimates by severity. Weighted average was used to calculate the average age and the overall prevalence of clinical symptoms and comorbidities. Median age of the studies populations (∼50 years old) was used to categorize the CHIKV patients into two groups, below and above the median age. The weighted average prevalence of each comorbidity was calculated (±SD) within each group. Publication bias was assessed both by the visual inspection of funnel plot (Supplementary Figure S1) and by Egger's test. Egger's test is widely used to assess the tendency for the effects estimated in small sample size studies to differ from those estimated in larger studies. The results of Egger's test are presented in terms of bias coefficient. Publication bias was only observed in studies identified to estimate the proportion of cardiac diseases. Meta-analyses were carried out to assess the pooled prevalence (and 95% CI) of clinical symptoms and the proportions of each comorbidity in the overall and severe cases. Meta-analysis tests were conducted using Comprehensive Meta-Analysis software, CMA version 3.9 (Englewood, NJ, USA) ([@bib0030]). Variances of raw proportions or percentages were pooled based on a binary random-effects model ([@bib0060]), given the population heterogeneity and assuming the relationships between comorbidities and CHIKV infections vary across populations. Forest plots were used to illustrate the prevalence of comorbidities in CHIKV from the selected studies in the entire patients and in severe cases.

Assessing the heterogeneity among the selected studies was carried out using the *Q* test ([@bib0055]) that informs about the presence versus the absence of heterogeneity. The *Q* test, however, does not report the extent of heterogeneity and has inadequate power to detect heterogeneity among the small number of studies identified for some comorbidities. Therefore, we calculated the *I^2^* index to complement the *Q* test and describe the degree of between-study heterogeneity ([@bib0120]). *I^2^* index values were categorized as low (0--30%), moderate (30--60%), substantial (60--90%), and considerable (\>90%) as recommended ([@bib0165]). We also quantified the true heterogeneity by estimating the between-study variance in the random-effects model (τ^2^), as previously described ([@bib0085]).

Results {#sec0030}
=======

Systematic analysis of studies that described the epidemiological, demographic and clinical features of CHIKV cases and reported the prevalence of a number of chronic diseases in the infectious disease, has identified 11 reports ([@bib0015], [@bib0100], [@bib0180], [@bib0130], [@bib0225], [@bib0200], [@bib0075], [@bib0050], [@bib0070], [@bib0245], [@bib0035]) with 2,773 patients ([Table 1](#tbl0005){ref-type="table"} ). This limited number of reports is the result of our strict search strategy and selection criteria and our focus only on the studies recording the prevalence of comorbidities in CHIKV. The majority of the cases were from South Asia, particularly India, followed by a significant number from South America. With the exception of a report from Brazil ([@bib0225]), the number of cases in the selected studies varied by ∼25-fold and ranged from 45 ([@bib0050]) to 1,111 ([@bib0180]) cases. The 1,111 cases from India ([@bib0180]) were not included in any meta-analysis since it was the only study referring to the prevalence of obesity in CHIKV. The sex ratio (male:female) was 0.83 with a weighted overall average age (±SD) of 42.9 ± 13.9 years (range: 21-70 years).Table 1Characteristics of the identified studies.Table 1Study \[Ref\]CountryDates (mm.yy)Number of SubjectsAge\
(yr)Clinical Symptoms (%)[d](#tblfn0020){ref-type="table-fn"}AllMFPyrexiaArthralgiaCephalgiaMyalgiaJoint EdemaDermatitisMalaise[@bib0225]Brazil01.16--03.1642253.310025502525[@bib0015]Puerto Rico06.14--09.14172819121.19391848368[@bib0200]Puerto Rico01.14--12.141801671366.3884169694477[@bib0075]Multiple[a](#tblfn0005){ref-type="table-fn"}01.14--11.1465412463[@bib0130]Haiti05.14--07.1453233053.291984751361749[@bib0050]Thailand04.09--06.094519264910010082[@bib0070]France03.05--12.0722711311450.2969974[@bib0180]India11.07--06.081,11130872345.56362[@bib0245]India01.06--12.061491084160[@bib0100]Reunion Island04.05--05.066102713397090131745[@bib0035]Reunion Island03.05--04.06157877057.9899647326312Total/Average/Overall Estimate[b](#tblfn0010){ref-type="table-fn"}03-05--03.162,7731,2201,47342.9 ± 13.9[c](#tblfn0015){ref-type="table-fn"}90.785.247.752.644.130.643.895% CI86.6--93.670.2--93.414.4--83.018.4--84.518.8--72.913.4--55.621.3--69.2*Q*7.516.22.92.11.89.14.4*I^2^*%6.256.80.00.00.022.831.5[^1][^2][^3][^4]

Meta-analysis for the identified studies showed that the most prevalent clinical symptoms were pyrexia (90.7%; 95% CI: 86.6-93.6%) and arthralgia (85.2%; 95% CI: 70.2-93.4%) with cephalgia, myalgia, joint edema, dermatitis and malaise in ∼30-50% of the cases. There was a small heterogeneity (Cochran's *Q*) in the estimates of clinical symptoms among the identified studies with an *I* ^2^ index varied up to 56.8% ([Table 1](#tbl0005){ref-type="table"}). As shown in [Figure 2](#fig0010){ref-type="fig"} (panel A), hypertension was the most prevalent comorbidity in CHIKV infection (31.3% of the cases; 95% CI: 17.9-48.8%) followed by diabetes (20.5%; 95% CI: 12.7-31.3%), cardiac diseases (14.8%; 95% CI: 8.1-25.5%) and asthma (only in 7.9% of the cases; 95% CI: 3.3-17.7). Prevalence of obesity was reported only in one of the identified studies ([@bib0180]). Characteristics of this study were mentioned in [Table 1](#tbl0005){ref-type="table"} but were excluded from any further meta-analysis given this limited data set. The prevalence of diabetes, hypertension, cardiac diseases and asthma varied by 25-, 5-, 28- and 50-fold among the identified studies, respectively. This wide among-studies variation in the proportion of comorbidities may have resulted in the heterogeneity (*I* ^2^ index) observed for the estimates of comorbidities that varied from 25.1% to 96.4% ([Figure 2](#fig0010){ref-type="fig"}). However, the true heterogeneity estimated by between-study variance in the random-effect model (τ^2^) was varied between 0.029 to 0.074 for the examined comorbidities. As shown in [Table 2](#tbl0010){ref-type="table"} , the proportion of diabetes, hypertension and cardiac diseases was 4- to 5-fold higher (*p \<*  0.05) in elder patients than their younger counterparts. We found a significant direct correlation between patients' age and the prevalence of diabetes (*r*  = 0.65, *p*  = 0.03), hypertension (*r*  = 0.68, *p*  = 0.033) and cardiac diseases (*r*  = 0.65, *p*  = 0.029) but inverse relationship (*r*  = −0.88, *p*  = 0.023) with asthma (data not shown).Figure 2Meta-analysis for the proportion of comorbidities in chikungunya cases.Weights are calculated from binary random-effects model analysis. Values represent proportions of diabetes, hypertension, cardiac diseases and asthma in all CHIKV cases (panel A) and severe cases (panel B) and 95% CI. Severity was defined as cases that underwent ICU, those with acute diseases, patients with complications and subjects with atypical CHIKV, joints involvement, hospitalization, and/or death. Analysis of heterogeneity is also presented as results of the *Q* test and the among-studies variation (*I^2^* index). Insert shows the odds ratio (OR and 95%CI) of developing severe CHIKV in patients with comorbidities.Figure 2Table 2Average age-associated prevalence of chronic morbidities in CHIKV.Table 2ComorbidityAge group\
(weighted average ± S.D.)\<50 years[a](#tblfn0025){ref-type="table-fn"}\
(44 ± 9)\>50 years[a](#tblfn0025){ref-type="table-fn"}\
(66 ± 5)*n*Prevalence (%)*n*Prevalence (%)Diabetes4446.7 ± 4.2116535.3 ± 8.9Hypertension27013.7 ± 7.7116149.1 ± 22.8Cardiac diseases4978.8 ± 6.3116132.7 ± 14.5Asthma45217.5 ± 8.97903.1[b](#tblfn0030){ref-type="table-fn"}[^5][^6]

Severe CHIKV cases were defined as cases that underwent ICU, those with acute diseases (*e.g.,* acute encephalitis) and subjects with atypical CHIKV (atypical clinical manifestations of CHIKV include vesiculobullous lesions, febrile seizures, and meningoencephalitis), joints involvement (e*.g.,* inflammatory joint destruction), hospitalization, and/or death (see above). Cases with severe CHIKV had a significantly higher proportion of diabetes (22.9% vs. 20.5%, *p \<*  0.05) ([Figure 2](#fig0010){ref-type="fig"}; panel B). Infected patients with diabetes (both types I and II, combined) -- but not those with hypertension or cardiac diseases -- had OR of 1.2 (95% CI: 1.05-1.48; *p*  = 0.0135) for developing severe CHIKV outcome compared to those with no diabetes.

Discussion {#sec0035}
==========

The present study was undertaken to systematically evaluate the prevalence of chronic comorbidities in CHIKV non-severe and severe cases of infection. Meta-analysis of the data extracted from the identified studies ([Figure 2](#fig0010){ref-type="fig"}) suggests that hypertension and diabetes are the most frequent comorbidities in patients with CHIKV infection with prevalence rates that varied from 20-30%. As expected, the prevalence of the examined chronic comorbidities was increased with age except for asthma. Although the reports identified here did not distinguish between the prevalence of type 1 and/or type 2 diabetes in CHIKV, results of the present study suggest an increased risk of developing severe CHIKV complications in people with diabetes (OR = 1.2; 95% CI: 1.05-1.48) than in those with other or no underlying chronic diseases. Similar observations were also reported in H1N1 ([@bib0020]), MERS-CoV ([@bib0025]) and influenza ([@bib0175]). For example, a recent study noted that, compared to subjects with no comorbidities, severe pandemic influenza cases are significantly elevated with obesity (OR for mortality 2.74; 95% CI: 1.56-4.80), cardiovascular diseases (2.92; 95% CI: 1.76-4.86), hypertension (1.49; 95% CI: 1.10-2.01) and neuromuscular disease (2.68; 95% CI: 1.91-3.75) ([@bib0175]). It may be worth noting that in CHIKV we identified only one study ([@bib0180]) evaluating the effect of overweight on disease severity and this was not included in any of our meta-analyses. This study reported a significant association between overweight and CHIKV sequelae (OR = 1.3; 95% CI: 1.2-1.4) ([@bib0180]). Chronic conditions influencing the severity of CHIKV such as diabetes were also noted to have similar effects in other respiratory illnesses ([@bib0020], [@bib0025], [@bib0175], [@bib0135]). Furthermore, a number of case-control studies demonstrated the incidence of metabolic syndrome and related diseases, *e.g.*, diabetes and hypertension, to be 2-fold higher in severe cases of dengue fever than in non-severe conditions ([@bib0105], [@bib0195]).

Although the prevalence of metabolic syndrome-related conditions such as diabetes, hypertension and cardiac diseases varied widely among the selected studies, the vast majority of the reports showed values clustering around the pooled estimated averages for each comorbidity, as evidenced by the low *I* ^2^ index values ([Figure 2](#fig0010){ref-type="fig"}). Comorbidities related to metabolic syndrome are thought to be etiologically linked to CHIKV pathogenesis. These disorders are known to downregulate key mediators of host innate immune response to pathogenesis. For example, diabetes, hyperglycemia and insulinopenia attenuate the synthesis of pro-inflammatory cytokines such as IFN-γ and interleukins to functionally impair the innate and humoral immune systems of the host ([@bib0020]). Furthermore, the cytokine overload related to the Th1 to Th2 shift in severe viral infection, when accompanied by the increased cytokine synthesis from metabolic diseases, can be detrimental in synergistically affecting the endothelium and leads to a range of subsequent complications related to both the infectious and chronic conditions ([@bib0260]). Furthermore, diabetes is known to impair macrophage and lymphocyte functions, subsequently reducing the host\'s immune response ([@bib0090]). This was noted when increased levels of HbA1c (*i.e.*, ≥9%) were linked to the severity of pneumonia ([@bib0005]). While diabetes may impair the immune system leading to increased level and duration of viremia, heart conditions and hypertension were thought to facilitate the passage of neurotropic viruses, e.g., flavivirus, across the blood-brain barrier to predispose patients to neurologic complications ([@bib0125]).

The present study has several limitations. The identified reports have shown a wide among-studies variance in the proportion of diabetes, hypertension, cardiac diseases and asthma, which may have contributed to the heterogeneity observed in the meta-analysis. Other sources of heterogeneity may be related to the large range of sample size and the different study designs. These factors may levy some limitations on the estimated contribution of chronic diseases to severe CHIKV cases and render our results as a guide to generate more accurate estimates for intervention strategies for infection in patients with chronic disorders. Furthermore, the small number of studies selected here did not allow us to evaluate the prevalence of chronic comorbidities in each outcome of the severe CHIKV cases. Additionally, little information was provided in the original articles on the chronic comorbidities in terms of how long patients were suffering from the condition(s), the onset of the condition(s) prior to or following CHIKV manifestation or whether or not the patients have received a treatment.

The study of comorbidities in CHIKV infection is important for reducing the burden of the disease via guiding approaches for improved patient outcome or differential case management. The present study provides evidence for a particular higher prevalence of diabetes in severe cases of CHIKV infections than in non-severe cases. The causal association, however, between chronic diseases and severe infection cannot be simply substantiated from these observations. However, even in the absence of causal inference between the non-communicable and infectious diseases, it may be justified that once non-severe episodes of infection are confirmed in subjects with diabetes that they remain under close surveillance to avert complications. This measure may prove important in averting severe disease outcome. Indeed, there are no current clear lines of prevention and treatment for CHIKV disease outside avoidance of mosquitoes and use of insect repellents. Coupling these practices with educating the public on the risk of severe infection can be an effective public health approach for the intervention of infection-related complications particularly in the middle- and low-income countries where the prevalence of chronic diseases is rising.
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[^1]: Multiple: Caribbean, United States, French West Indies.

[^2]: Overall estimate is calculated from meta-analysis of the proportions using the binary random-effects model.

[^3]: Weighted average ± SD.

[^4]: Empty cells denote data not available in the original study.

[^5]: Median age of the subjects from the selected studies (∼50 years). Number in parentheses is weighted average ± SD of patients' ages within the group.

[^6]: Weighted average from only two studies. Differences between the two age groups are significant (p \< 0.05) for all comorbidities (except asthma where assessment cannot be made due to the small number of studies in the elder group).
